FREE SHIPPING ON ORDERS OVER $300

Retatrutide

SKU RT Category

Price range: $160.00 through $450.00

Amino Acid Sequence:

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-γ-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Chemical Formula:

C₂₂₁H₃₄₂N₄₆O₆₈

CAS Registry Number:

2381089-83-2

  • Obesity & severe obesity

  • Type 2 diabetes & glycemic control

  • Cardiometabolic disease risk reduction

  • Obstructive sleep apnea

  • Osteoarthritis associated with metabolic dysfunction

  • NAFLD / metabolic liver disease

Triple‑Agonist Activity

  • GLP‑1 receptor activation: appetite suppression, delayed gastric emptying, improved glycemic control

  • GIP receptor activation: enhanced insulin response, metabolic synergy with GLP‑1

  • Glucagon receptor activation: increased energy expenditure and fat oxidation

Metabolic Synergy

  • Combines satiety, thermogenesis, and glucose regulation

  • Drives deeper and more sustained weight‑loss effects than single‑pathway agents

Cardiometabolic Influence

  • Improves lipid profiles

  • Reduces inflammatory markers

  • Supports metabolic organ health (liver, cardiovascular system)

Retatrutide is an investigational therapeutic and is not FDA‑approved. It is currently in Phase 3 clinical trials, with regulatory submissions anticipated in 2025–2026 and potential approval in 2026–2027, pending trial outcomes. Despite its investigational status, Retatrutide has generated significant global interest due to its record‑setting clinical results and transformative potential in obesity and metabolic‑disease research.

1. “What to Know About Retatrutide.” Health news and medical overview article summarizing mechanism, clinical trial data, and development status. www.Lilly.com
2. Coskun, T., Sloop, K. W., Loghin, C., Alsina‑Fernandez, J., Urva, S., et al. (2023). Retatrutide, a GIP, GLP‑1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double‑blind, placebo‑ and active‑controlled, parallel‑group, phase 2 trial conducted in the USA. The Lancet, 402(10397), 123–135.
3. “Retatrutide (GLP‑3): Next‑Generation Triple‑Agonist for Obesity and Diabetes.” Scientific and clinical overview of retatrutide’s mechanism and therapeutic potential. Metabolic Therapeutics Review.
4. Srivastava, G., & Apovian, C. M. (2024). Retatrutide—A game changer in obesity pharmacotherapy. Obesity Reviews / PMC Commentary.
5. Perakakis, N., et al. (2023). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double‑blind, parallel‑group, placebo‑controlled, randomised trial. The Lancet Diabetes & Endocrinology, 11(10), 765–777.
6. “Retatrutide FDA Approval Timeline & Status 2025–2027.” Regulatory status summary and projected approval timeline. Honest Care Medical Insights.
7. “Retatrutide Approval Tracker: FDA, EMA, TGA Status (2025).” Regulatory tracking report summarizing global approval progress. Retatrutide Journal.
8. “Retatrutide 2026 Update: Everything We Know After Phase 3.” Comprehensive update on Phase 3 outcomes, safety data, and expected regulatory milestones. Clinical Therapeutics Update.

CURRENT BATCH LOT NUMBERS: 

RETATRUTIDE 10 MG: RT102026-05-04

RETATRUTIDE 20 MG: RT202026-02-02

RETRATUTIDE 40 MG: RT402026-06-01

 

 

CERTIFICATES OF ANALYSIS: 

CERTIFICATE OF ANALYSIS – TGMPURE RETATRUTIDE 10 MG (RT102026-05-04)

CERTIFICATE OF ANALYSIS – TGM PURE – ENDOTOXINS – RETATRUTIDE 2O MG (RT2002026-02-02)

CERTIFICATE OF ANALYSIS – TGM PURE – QUANTITATIVE – RETATRUTIDE 2O MG (RT2002026-02-02

CERTIFICATE OF ANALYSIS: TGMPURE RETATRUTIDE 40 MG (RT402026-06-01)

full product description

Retatrutide (LY3437943) is an investigational triple‑agonist peptide that simultaneously activates the GLP‑1, GIP, and glucagon receptors, representing the next generation of incretin‑based metabolic therapeutics. This multi‑pathway design aims to surpass the efficacy of single‑ and dual‑agonist drugs by combining appetite suppression, enhanced energy expenditure, and improved glycemic control. Retatrutide is currently in Phase 3 clinical trials as part of Eli Lilly’s TRIUMPH program, with projected regulatory submissions expected in late 2025–2026 and potential approval in 2026–2027, depending on trial outcomes. It is not FDA‑approved as of the latest updates.

Phase 3 data released in late 2025 demonstrated unprecedented weight‑loss outcomes, with TRIUMPH‑4 reporting ~28.7% average weight reduction, the highest recorded in any obesity trial to date.  Ongoing trials are evaluating its impact on obesity, type 2 diabetes, sleep apnea, osteoarthritis, and cardiometabolic complications.

Retatrutide offers the most powerful weight‑loss and metabolic‑improvement profile seen in clinical trials to date, driven by its triple‑agonist mechanism. Early data suggest transformative potential for obesity and multiple metabolic comorbidities.

Join Waitlist We will inform you when the product arrives in stock. Please leave your valid email address below.